ArticleBritish journal of haematology2026
Clinical features and prognostic factors of adult systemic chronic active EBV disease: A retrospective analysis in Japan.
Article in British journal of haematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
Systemic chronic active Epstein-Barr virus disease (sCAEBV) is a life-threatening disorder characterized by Epstein-Barr virus (EBV) infection in T cells and/or natural killer (NK) cells leading to systemic inflammation. We retrospectively analysed 46 adult patients diagnosed with sCAEBV at two high-volume centres in Japan. Patients with active disease received immunosuppressive therapy, chemotherapy-based regimens and/or ruxolitinib. Allogeneic haematopoietic stem cell transplantation (allo-HSCT) was pursued whenever feasible. Of 46 patients, 41 (89.1%) ultimately underwent allo-HSCT. Five patients progressed from hydroa vacciniforme lymphoproliferative disorder (HV-LPD); all showed EBV-infected CD4+ cells. The 3-year overall survival (OS) was 43.1% (95% confidence interval [CI], 27.7-57.5), and all patients who did not undergo allo-HSCT died within 8 months from diagnosis. Five patients (10.9%) developed lymphoma or leukaemia. Leading causes of death included haemophagocytic lymphohistiocytosis and infections. Multivariable analysis identified high alanine aminotransferase (ALT) and ferritin as independent predictors of poor outcome. Based on these findings, we developed a risk model stratifying patients into three groups with distinct 3-year OS rates: 69.9% (95% CI, 44.6-85.3) in patients with neither factor, 24.8% (95% CI, 7.0-48.2) in those with one factor and 0% in those with both factors (p < 0.001). ALT and ferritin are practical biomarkers for risk stratification and treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.